Although HCV-related cirrhotic patients can achieve a sustained virological response (SVR) to IFN-based anti-HCV therapy, the risk of cirrhosis regression and liver cancer may still exist. A long-term follow-up study recommends that cirrhotic patients who achieve an SVR to anti-HCV treatment should continue with regular observation for hepatocellular carcinoma (HCC).1 This study reports cirrhosis regression … Continue reading Hepatocellular Carcinoma Risk Persists in Patients With HCV-Related Cirrhosis